Can a cholesterol drug tame inflammation in diabetes? small study investigates
Knowledge-focused
Completed
This completed Phase 4 trial looked at how evolocumab (Repatha), a cholesterol-lowering drug, affects markers of inflammation and blood clotting in 41 people with type 2 diabetes and heart disease. Participants received either evolocumab or a placebo injection every 4 weeks for 1…
Phase: PHASE4 • Sponsor: Robert Rosenson • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC